![](https://endpts.com/wp-content/uploads/2018/10/esmo-2018-credit-esmo-tile.jpg)
Winners and losers at #ESMO18
MUNICH — AstraZeneca has followed up on its breakthrough approval for Lynparza — the first of the PARP wave that arrived on the market 4 years ago — with the rollout of impressive frontline data for ovarian cancer.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.